HK1189056A1 - 作為藥物對呋咱並苯並咪唑響應的生物標記的用途 - Google Patents

作為藥物對呋咱並苯並咪唑響應的生物標記的用途

Info

Publication number
HK1189056A1
HK1189056A1 HK14102070.3A HK14102070A HK1189056A1 HK 1189056 A1 HK1189056 A1 HK 1189056A1 HK 14102070 A HK14102070 A HK 14102070A HK 1189056 A1 HK1189056 A1 HK 1189056A1
Authority
HK
Hong Kong
Prior art keywords
bubr1
furazanobenzimidazoles
biomarker
drug response
drug
Prior art date
Application number
HK14102070.3A
Other languages
English (en)
Inventor
Heidi Alexandra Lane
Felix Bachmann
Madlaina Breuleux
Michael Boutros
Daniel Gilbert
Xian Zhang
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of HK1189056A1 publication Critical patent/HK1189056A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
HK14102070.3A 2011-01-21 2014-03-03 作為藥物對呋咱並苯並咪唑響應的生物標記的用途 HK1189056A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151677 2011-01-21
PCT/EP2012/050818 WO2012098207A1 (en) 2011-01-21 2012-01-19 Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles

Publications (1)

Publication Number Publication Date
HK1189056A1 true HK1189056A1 (zh) 2014-05-23

Family

ID=43920866

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14102070.3A HK1189056A1 (zh) 2011-01-21 2014-03-03 作為藥物對呋咱並苯並咪唑響應的生物標記的用途

Country Status (13)

Country Link
US (2) US10222377B2 (zh)
EP (1) EP2666016B1 (zh)
JP (1) JP6302673B2 (zh)
CN (1) CN103314295B (zh)
AU (1) AU2012208520B2 (zh)
CA (2) CA2822491C (zh)
DK (1) DK2666016T3 (zh)
ES (1) ES2620582T3 (zh)
HK (1) HK1189056A1 (zh)
HU (1) HUE032643T2 (zh)
PL (1) PL2666016T3 (zh)
PT (1) PT2666016T (zh)
WO (1) WO2012098207A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2691533T3 (pl) * 2011-03-29 2017-09-29 Basilea Pharmaceutica Ag Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na leki
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
WO2017068182A1 (en) 2015-10-22 2017-04-27 Basilea Pharmaceutica Ag Use of eb1 as a biomarker of drug response
CN116947836A (zh) 2017-04-26 2023-10-27 巴斯利尔药物国际股份公司 制备呋咱并苯并咪唑及其晶型的方法
EP3624790A1 (en) 2017-05-16 2020-03-25 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
CN107119137B (zh) * 2017-05-26 2018-04-06 广州华弘生物科技有限公司 一种快速检测HER‑2/neu基因表达的检测试剂盒
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508658A (ja) * 1997-06-11 2002-03-19 カイロン コーポレイション 野生型ｈｕＢＵＢ１遺伝子の減少の検出
AU1614099A (en) 1997-12-01 1999-06-16 Fox Chase Cancer Center Novel genes encoding proteins involved in mitotic checkpoint control and methodsof use thereof
CN101732717A (zh) * 2001-02-21 2010-06-16 诺华疫苗和诊断公司 用于诊断和作为癌症治疗靶标的ttk
US7407946B2 (en) * 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
PT1636215E (pt) * 2003-05-23 2008-04-29 Basilea Pharmaceutica Ag Furazanobenzimidazoles
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US8021831B2 (en) * 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
CN102747141A (zh) 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
AU2009264431B2 (en) * 2008-06-26 2013-11-07 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
MX336240B (es) 2009-07-27 2016-01-13 Basilea Pharmaceutica Ag Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas.

Also Published As

Publication number Publication date
JP6302673B2 (ja) 2018-03-28
CA3142576A1 (en) 2012-07-26
US20140045897A1 (en) 2014-02-13
US20160320397A1 (en) 2016-11-03
DK2666016T3 (en) 2017-04-10
WO2012098207A1 (en) 2012-07-26
US9970938B2 (en) 2018-05-15
PL2666016T3 (pl) 2017-07-31
AU2012208520B2 (en) 2016-03-10
EP2666016B1 (en) 2017-01-04
PT2666016T (pt) 2017-04-03
CN103314295A (zh) 2013-09-18
AU2012208520A1 (en) 2013-07-04
JP2014505877A (ja) 2014-03-06
ES2620582T3 (es) 2017-06-29
CA2822491C (en) 2023-02-14
NZ611805A (en) 2015-05-29
CA2822491A1 (en) 2012-07-26
EP2666016A1 (en) 2013-11-27
US10222377B2 (en) 2019-03-05
CN103314295B (zh) 2016-03-16
HUE032643T2 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
GB201113928D0 (en) Improvements relating to graphical user interfaces
EP2761911A4 (en) PERSONAL SALES POINT
EP2795476A4 (en) USE OF CONSISTENCY MEMORY EXTRACTS OF A COMMON VOLUME
HK1189056A1 (zh) 作為藥物對呋咱並苯並咪唑響應的生物標記的用途
HK1191096A1 (zh) 乙酰化微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途
BR112014003878A2 (pt) síntese de r-bifenilalaninol
HK1192323A1 (zh) -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途
GB201105576D0 (en) Parallel computation of matrix problems
HK1185947A1 (zh) 作為呋咱並苯並咪唑類藥物應答的生物標記的用途
EP2743639A4 (en) CONSTRUCTION OF A WAY MONITORING ELECTRODE
EP2773262A4 (en) ASSESSMENT OF A CARDIAL STRUCTURE
ZA201306520B (en) Use of phospho-akt as a biomarker of drug response
PL2753330T3 (pl) Terapeutyczne zastosowania ektoiny
GB2489486B (en) Improvements relating to construction
HK1203355A1 (zh) '- '-去鐵硫素類似物的用途
PL2583571T3 (pl) Ulepszenia dotyczące czapsów
GB2488866B (en) Use of GPS to detect repetitive motion
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
IL222506A0 (en) Alternative to tetrazene
EP2809685A4 (en) ELECTROCHEMICAL SYNTHESIS OF CHLORO-CHITOSAN
EP2791349A4 (en) SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
EP2928469A4 (en) POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS
EP2702991A4 (en) COMPOSITION OF ENTACOPONE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240125